State Street Corp Acquires 4,903 Shares of BioSig Technologies Inc (NASDAQ:BSGM)

State Street Corp raised its holdings in shares of BioSig Technologies Inc (NASDAQ:BSGM) by 1.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 279,024 shares of the company’s stock after acquiring an additional 4,903 shares during the quarter. State Street Corp owned about 1.07% of BioSig Technologies worth $1,169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Barclays PLC raised its holdings in BioSig Technologies by 105.0% during the 4th quarter. Barclays PLC now owns 15,863 shares of the company’s stock valued at $94,000 after acquiring an additional 8,124 shares during the period. Mayo Clinic bought a new stake in BioSig Technologies during the 4th quarter valued at $1,199,000. BlackRock Inc. raised its holdings in BioSig Technologies by 1.9% during the 1st quarter. BlackRock Inc. now owns 890,012 shares of the company’s stock valued at $3,728,000 after acquiring an additional 17,014 shares during the period. Cambridge Investment Research Advisors Inc. raised its holdings in BioSig Technologies by 17.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,000 shares of the company’s stock valued at $444,000 after acquiring an additional 16,000 shares during the period. Finally, UBS Group AG raised its holdings in BioSig Technologies by 97.5% during the 4th quarter. UBS Group AG now owns 24,432 shares of the company’s stock valued at $145,000 after acquiring an additional 12,064 shares during the period. 14.98% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:BSGM opened at $7.20 on Wednesday. BioSig Technologies Inc has a 52-week low of $2.36 and a 52-week high of $12.43. The firm has a fifty day moving average of $10.27 and a 200 day moving average of $6.55. The company has a current ratio of 10.45, a quick ratio of 9.95 and a debt-to-equity ratio of 0.01.

BioSig Technologies (NASDAQ:BSGM) last announced its earnings results on Monday, May 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.22). As a group, equities analysts anticipate that BioSig Technologies Inc will post -1.03 earnings per share for the current fiscal year.

In other BioSig Technologies news, CEO Kenneth L. Londoner purchased 4,000 shares of the business’s stock in a transaction on Friday, May 29th. The stock was acquired at an average cost of $9.38 per share, for a total transaction of $37,520.00. Also, CEO Kenneth L. Londoner purchased 3,600 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were acquired at an average price of $10.84 per share, with a total value of $39,024.00. Following the completion of the transaction, the chief executive officer now owns 1,276,158 shares of the company’s stock, valued at $13,833,552.72. The disclosure for this purchase can be found here. Insiders purchased 8,600 shares of company stock valued at $87,034 over the last quarter. 19.49% of the stock is owned by company insiders.

Several research firms have recently weighed in on BSGM. Zacks Investment Research cut shares of BioSig Technologies from a “buy” rating to a “hold” rating in a report on Monday, May 25th. Roth Capital began coverage on shares of BioSig Technologies in a report on Monday, March 30th. They issued a “buy” rating and a $9.00 price target on the stock. BidaskClub cut shares of BioSig Technologies from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Finally, ValuEngine raised shares of BioSig Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, April 1st.

About BioSig Technologies

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Read More: Dividend Yield

Want to see what other hedge funds are holding BSGM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSig Technologies Inc (NASDAQ:BSGM).

Institutional Ownership by Quarter for BioSig Technologies (NASDAQ:BSGM)

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.